Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Memorial Sloan Kettering Cancer Center patents


Recent patent applications related to Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering Cancer Center is listed as an Agent/Assignee. Note: Memorial Sloan Kettering Cancer Center may have other listings under different names/spellings. We're not affiliated with Memorial Sloan Kettering Cancer Center, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Memorial Sloan Kettering Cancer Center-related inventors


 new patent  Nanoparticle immunoconjugates

Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached... Memorial Sloan Kettering Cancer Center

 new patent  Systems and methods for determining optimum patient-specific antibody dose for tumor targeting

The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue)... Memorial Sloan Kettering Cancer Center

Compositions and methods for treatment of glioma

In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a CSF-IR inhibitor together with one or more additional active agents such as IGF-IR inhibitors, PI3K inhibitors, IL4 inhibitors, NFAT inhibitors, and/or Stat6... Memorial Sloan Kettering Cancer Center

Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Disclosed herein are methods of treating an EBV-LPD (Epstein-Barr Virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the EBV-LPD and/or radiation therapy to treat the EBV-LPD, comprising administering to the human patient a population of allogeneic T cells comprising EBV-specific T cells.... Memorial Sloan Kettering Cancer Center

Methods and compositions for theranostic nanoparticles

Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.... Memorial Sloan Kettering Cancer Center

Compositions and methods for altering second messenger signaling

The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.... Memorial Sloan Kettering Cancer Center

Compositions and methods for altering second messenger signaling

The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.... Memorial Sloan Kettering Cancer Center

Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof

The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs... Memorial Sloan Kettering Cancer Center

Antibodies targeting b-cell maturation antigen and methods of use

The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.... Memorial Sloan Kettering Cancer Center

Anti-muc16 antibodies and uses thereof

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.... Memorial Sloan Kettering Cancer Center

Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors

The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAAE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to... Memorial Sloan Kettering Cancer Center

Newcastle disease viruses and uses thereof

Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such... Memorial Sloan Kettering Cancer Center

Synergistic cancer treatment

The use of mitogen activated kinase inhibition therapy in combination with receptor tyrosine kinase therapy for the treatment of cancer is described.... Memorial Sloan Kettering Cancer Center

Methods and systems for retrospective internal gating

The present invention, in one form, is a method for deriving respiratory gated PET image reconstruction from raw PET data. In reconstructing the respiratory gated images in accordance with the present invention, respiratory motion information derived from individual voxel signal fluctuations, is used in combination to create usable respiratory phase... Memorial Sloan Kettering Cancer Center

Compositions and methods for treatment of edema

Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-β agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.... Memorial Sloan Kettering Cancer Center

Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use

Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., −55 mV). These nanoparticles are highly soluble in water,... Memorial Sloan Kettering Cancer Center

Compositions and methods for nanoparticle-based drug delivery and imaging

Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nanoparticles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. The polysaccharide is able to retain cargo (drugs, diagnostics, etc.) without chemical modification of the agent. The... Memorial Sloan Kettering Cancer Center

Methods of treating and prognosing nonhematopoietic malignant tumors

Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.... Memorial Sloan Kettering Cancer Center

Small-molecule hsp90 inhibitors

Hsp90 inhibitors havin are rovided havin the formula: (I) with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and 5′ positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy,... Memorial Sloan Kettering Cancer Center

Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Described herein are antibodies that bind chondroitin sulfate proteoglycan 4 (CSPG4) and, in particular, chimeric and humanized anti-CSPG4 antibodies and fragments thereof. Also provided herein are methods of using individual humanized antibodies or compositions thereof for the detection, prevention, and/or therapeutic treatment of CSPG4-related diseases, in particular, melanoma.... Memorial Sloan Kettering Cancer Center

Immunogenic wt-1 peptides and methods of use thereof

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.... Memorial Sloan Kettering Cancer Center

Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer

The present invention is directed to methods and compositions for treating cancer, including, hematologic malignancies, such as B-cell malignancies, with anti-tumor antibody-tumor suppressor fusion proteins in order to selectively restore tumor suppressor gene function to cancer cells in which such tumor suppressor gene function has been lost. The present invention... Memorial Sloan Kettering Cancer Center

Method for enhancing electrospray

Provided herein, among other things, is a method of ionizing a first stream of liquid by an electrospray ion source having a nebulizer, wherein the first stream of liquid may comprise an analyte. In some embodiments, the method may comprise: a) providing the first stream of liquid to the nebulizer;... Memorial Sloan Kettering Cancer Center

Methods of selecting t cell line and donor thereof for adoptive cellular therapy

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having... Memorial Sloan Kettering Cancer Center

Hsp90-targeted inflammation and infection imaging and therapy

The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection.... Memorial Sloan Kettering Cancer Center

Radiohalide-labeled targeted diagnostics and therapeutics

Disclosed are chemical entities of formula (I) wherein R1, R2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1... Memorial Sloan Kettering Cancer Center

Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes

The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize... Memorial Sloan Kettering Cancer Center

Psma-related therapies

The present invention provides methods of treating disease by modulation of PSMA activity. Such modulations can lead to, for example, alterations in cancer tumor metabolism, oxygenation, vascularization, and metastasis. The present invention encompasses the recognition that PSMA, through its role in a complex signaling cascade, can affect cancer progression, angiogenesis,... Memorial Sloan Kettering Cancer Center

Anti-gd2 antibodies

In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.... Memorial Sloan Kettering Cancer Center

Antibodies, compositions, and uses

The present disclosure describes anti-B7H3 antibody agents and uses relating thereto. Among other things, the present disclosure demonstrates particular immunomodulatory effectiveness of certain such antibodies. The present disclosure further describes particularly high-affinity or otherwise useful antibodies and antibody agents based thereon, including particularly certain humanized and/or affinity matured versions of... Memorial Sloan Kettering Cancer Center

Hsp70 modulators and methods for making and using the same

The present invention provides compounds I and II and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a... Memorial Sloan Kettering Cancer Center

Bispecific her2 and cd3 binding molecules

Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and... Memorial Sloan Kettering Cancer Center

Kits for neural conversion of human embryonic stem cells

The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for... Memorial Sloan Kettering Cancer Center

Apparatus, providing laser steering and focusing for incision, excision and ablation of tissue in minimally-invasive surgery

Provided and described herein are exemplary embodiments of apparatus, system, computer-accessible medium, procedure and method according to the present disclosure which can be used for providing laser steering and focusing for e.g., incision, excision and/or ablation of tissue in minimally-invasive surgery. For example, an exemplary apparatus is provided that can... Memorial Sloan Kettering Cancer Center

Methods of treating cmv retinitis by t cell therapy

Disclosed herein are methods of treating CMV (cytomegalovirus) retinitis in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV-specific T cells, wherein the human patient is infected with HIV or has been the recipient of a solid organ transplant.... Memorial Sloan Kettering Cancer Center

05/11/17 / #20170130199

Methods for neural conversion of human embryonic stem cells

The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for... Memorial Sloan Kettering Cancer Center

03/30/17 / #20170087159

Platelet-derived growth factor receptor mutations and compositions and methods relating thereto

In certain embodiments the present invention involves methods of killing tumor cells that comprise an oncogenic PDGFR mutation, and methods of treating subjects having tumors that comprise such tumor cells. In some embodiments such methods involve using PI3K inhibitors, or a combination of a PI3K inhibitor and an mTOR inhibitor,... Memorial Sloan Kettering Cancer Center

03/30/17 / #20170088630

T cell receptor-like antibodies specific for a wti peptide presented by hla-a2

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion... Memorial Sloan Kettering Cancer Center

03/23/17 / #20170081409

Anti-pd-1 antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.... Memorial Sloan Kettering Cancer Center

01/26/17 / #20170022475

Modulating cell proliferation and pluripotency

Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.... Memorial Sloan Kettering Cancer Center








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Memorial Sloan Kettering Cancer Center in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Memorial Sloan Kettering Cancer Center with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###